Pharmacist Moms Group

Videos
View More
Precision Oncology in Focus: ctDNA's Role in Colon Cancer Management

Sasha Watson, PharmD, BCOP, discusses the emerging role of circulating tumor DNA (ctDNA) in colon cancer, highlighting its potential to enhance precision oncology by improving early detection, guiding adjuvant therapy decisions, and monitoring disease recurrence and treatment resistance.

Asembia AXS25: Leveraging Advanced Analytics and Data Insights to Improve Specialty Pharmacy Patient Outcomes

Specialty pharmacies can leverage advanced analytics, AI, and comprehensive data insights to create targeted clinical programs.

Asembia AXS25: Strategic Partnerships Driving Pharmaceutical Innovation

Specialty distributors provide strategic partnerships that enhance pharmaceutical manufacturers' ability to bring innovative medicines to market.

Asembia AXS25: Navigating Challenges in Cell and Gene Therapy

Experts emphasize the need to understand patient journeys, navigate complex value chains, and strategically match the right patients with groundbreaking therapies.

Asembia AXS25: Pharmacy Perspectives on the Inflation Reduction Act

Experts share operational challenges and patient care implications of the Inflation Reduction Act's (IRA) drug pricing reforms.

Asembia AXS25: Navigating the Evolving Landscape of GLP-1 Medications
Asembia AXS25: Advancing nAMD and DME Treatments: Pharmacists' Role in Patient Care and Therapy Optimization
Important Treatment Considerations With LDL-C– Lowering Therapies

Panelists discuss how the initiation of statin therapy requires careful consideration of contraindications and patient-specific factors, particularly in those with liver disease, renal impairment, or advanced age, while noting evolving treatment patterns toward more intensive low-density lipoprotein cholesterol (LDL-C)–lowering therapies based on individualized risk assessment.

Weighing the Benefits and Risks of Statin Therapy

Panelists discuss how statin therapy for primary prevention requires careful consideration of cardiovascular risk factors against potential adverse effects such as myalgia and liver abnormalities, generally favoring treatment when the calculated 10-year atherosclerotic cardiovascular disease [ASCVD] risk exceeds 7.5% to10% and adjusting recommendations based on individual patient factors including age, comorbidities, and preferences.

Official Media Partner

Official Media Partner

Official CE Partner

Official CE Partner

Founder of Women Pharmacist Day

Founder of Women Pharmacist Day
pharmacist moms group logo
Stay In Touch
an mjh life sciences brand

© 2021 MJH Life Sciences and Pharmacy Times®. All rights reserved.

Privacy Policy